Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.eimce.2022.07.006 http://scihub22266oqcxt.onion/10.1016/j.eimce.2022.07.006 35906174!9315338!35906174     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Enferm+Infecc+Microbiol+Clin+(Engl+Ed) 2023 ; 41 (5): 301-304 Nephropedia Template TP {{tp|p=35906174|t=2023. The new generation of messenger RNA (mRNA) vaccines against influenza |pdf=|usr=}}{{35906174}} gab.com Text The new generation of messenger RNA (mRNA) vaccines against influenza JO: Enferm Infecc Microbiol Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=35906174 #FOAvip Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines. Twit Text FOAVip The new generation of messenger RNA (mRNA) vaccines against influenza ????Enferm Infecc Microbiol Clin (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=35906174 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35906174 #FOAvip English Wikipedia <ref>{{Cite pmid|35906174}}</ref> The new generation of messenger RNA (mRNA) vaccines against influenza #MMPMID35906174 Reina J Enferm Infecc Microbiol Clin (Engl Ed) 2023[May]; 41 (5): 301-304 PMID35906174show ga Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines. |*COVID-19/prevention & control[MESH] |*Influenza Vaccines[MESH] |*Influenza, Human/prevention & control[MESH] |Animals[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH] |RNA, Messenger/genetics[MESH] |SARS-CoV-2[MESH]The new generation of messenger RNA (mRNA) vaccines against influenza (epmc).pdf DeepDyve Pubget Overpricing